StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Trading Down 4.4 %

TRVN opened at $1.30 on Wednesday. The business’s 50 day moving average is $1.67 and its 200-day moving average is $2.24. The stock has a market cap of $1.12 million, a PE ratio of -0.03 and a beta of 1.05. Trevena has a twelve month low of $1.13 and a twelve month high of $14.14.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.